Tradestie Institutional Equity Comparison Engine

CDNL vs ECG โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ECG Overall Edge

ECG Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Everus Construction Group, Inc. (ECG) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CDNL trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ECG at 10.8x Forward P/E and 8.2% operating margin (+40.3% YoY). In options structure, CDNL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ECG sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ECG
CDNL N/M vs ECG 10.8x Fwd P/E
Growth & Margin Winner ECG
Op Margin N/A vs 8.2% ยท YoY N/A vs +40.3%
Momentum & Technical Winner ECG
1Y -79.6% vs -9.5% ยท 52W Pos 0% vs 6%
Options & Structure Winner ECG
UNCLASSIFIED (N/A IV) vs BREAKDOWN (6th %ile IV)
CDNL US Equity
CDNL
Institutional Equity
$4.75
-8.4% 1D
Market Cap N/A
1M Return -65.34%
1Y Return -79.57%
Forward P/E N/M
Unified AI Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 55.0
ECG NYSE
Everus Construction Group, Inc.
Operative Builders
$76.59
-8.66% 1D
Market Cap $4.3B
1M Return -21.08%
1Y Return -9.5%
Forward P/E 10.8x
Unified AI Score
50.0 / 100 HOLD
Tech 73.0 Fund 64.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CDNL -79.57% ECG -9.5% Spread: +61.76 pp (ECG Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CDNL TTM Op. Margin: N/A ECG TTM Op. Margin: 8.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDNL vs ECG. Trailing 12-month operating profitability (CDNL N/A vs ECG 8.2%) and valuation multiples (CDNL N/M vs ECG 10.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CDNL (0) vs ECG (10)
Institutional Metric CDNL ECG Criterion Row Winner
Market Capitalization Scale N/A $4.3B Larger Scale ECG
Trailing P/E Ratio Valuation N/M 15.1x Lower Multiple ECG
Forward P/E Ratio Valuation N/M 10.8x Lower Multiple ECG
Revenue Growth (YoY) Growth N/A +40.3% Higher Growth ECG
Operating Margin (TTM) Profitability N/A 8.2% Higher Margin ECG
Net Profit Margin Profitability N/A 6.2% Higher Margin ECG
Return on Equity (ROE) Capital Efficiency N/A 40.3% Higher ROE ECG
52-Week Range Position Momentum 0% ($5โ€“$96) 6% ($70โ€“$172) Stronger Trend ECG
Beta / 30D Volatility Risk Regime 2.65ฮฒ ยท 238% Vol 2.17ฮฒ ยท 127% Vol Lower Realized Risk ECG
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 50.0 / 100 (HOLD) Higher Composite ECG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CDNL vs ECG Buy Guide
CDNL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDNL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ECG BREAKDOWN
138d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ECG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CDNL nor ECG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.